Deepa Prasad is a Managing Director at WestRiver Group (WRG), leading investments in healthcare innovation. Deepa led WRG’s investments in Design Therapeutics (NASDAQ: DSGN), Ginger, and Curai. She currently sits on the Board of Design Therapeutics and as a Board Observer of Viome. In June 2021, she was awarded the Falk Marques General Partners Rising Star Award sponsored by Deloitte.
Deepa brings over 20 years of healthcare experience spanning investment banking, general management, startups and legislation. Her previous roles include: Chief of Staff at Blue Shield with $21B in revenue, General Manager / Regional VP at Optum (NYSE: UNH), Head of Managed Care at California Hospital Association (one of the largest healthcare lobbyists in the U.S.), and VP of Financial Strategy and Business Development at Coherus Biosciences (NASDAQ: CHRS). For the majority of her career, Deepa worked in healthcare investment banking focusing on biotech private placements and buyside/sellside M&A.
Deepa currently serves on the Committee for Innovation and Entrepreneurship at UC Davis and as a Charter Member for TiE, a non-profit global network of entrepreneurs and VCs. She earned her bachelor’s degree in Business Administration from the University of California, Berkeley and her MBA from the Kellogg School of Management at Northwestern University with an emphasis in Health Industry Management.
WestRiver Group is a collaboration of leading investment firms that provides integrated capital solutions to the innovation economy.